An observational study in Osteoporosis and Inflammatory Rheumatism, sponsored by Prof Dr Frank Buttgereit. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Prof Dr Frank Buttgereit · Observational
Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Po…PubMed 35159345 ↗; 4 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Osteoporosis with a site in Germany — 7 open to participants now, 12 under way, none of them phase 3. Osteoporosis · Germany.
Among the 55 studies in Osteoporosis with a site in Germany, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2015, is one of 17 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 38th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →7 of the 55 studies in Osteoporosis with a site in Germany are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in Germany, United States, Argentina and 11 more countries
Ages 50+
Amber Implants B.V. · Sites in Germany, France
Ages 21–85
Bundeswehr University Munich · Sites in Germany
Ages 18–35 · Women only · Healthy volunteers
University Hospital, Bonn · Sites in Germany
Ages 18+
AgNovos Healthcare, LLC · Sites in Germany, Austria, Belgium and 8 more countries
Ages 65–91 · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 160 across 456 observational studies indexed under Osteoporosis.
Median enrollment 222 across the 38 interventional studies, 144 across the 17 observational. Of the 39 that completed or were terminated, 14 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 55 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Prof Dr Frank Buttgereit as lead sponsor.
Prof Dr Frank Buttgereit has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteoporosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
| NCT07301749Amber Implants B.V.A Clinical Study Evaluating the Safety and Efficacy of the VCFix Spinal System for Treatment of Vertebral Compression Fractures | 2027-07-31 |
| NCT07897929Wolfgang Kemmler, PhDExercise and Fall Prevention for Fracture Reduction | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Osteoporosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis), since GIOP is counted among the two most important adverse effects of glucocorticoid therapy, by both rheumatologists and patients. The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.
Patients with chronic inflammatory rheumatic diseases or psoriasis treated with glucocorticoids
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Every patient has to fulfill the following inclusion criteria:
Exclusion Criteria:
If any of the following exclusion criteria is true, the patient must not be included in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
Drug: Glucocorticoid treatment
Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
Drug: Glucocorticoid treatment
Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
Glucocorticoid treatment
Also known as: prednis(ol)one, methylprednisolone
Bone mineral density
T-score (measured by DEXA; statistical evaluation on group levels, lower values are considered as being more dangerous)
Time frame: 2 - 5 years
Mean daily glucocorticoid dosage
Mean daily dosage in milligram prednisone equivalent per day (measured by questionnaire; averaged values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)
Time frame: 1 day - 25 years
Cumulative glucocorticoid dosage
Cumulative glucocorticoid dosage in gram (measured by questionnaire; summed values are calculated; statistical evaluation on group levels, higher values are considered as being more dangerous)
Time frame: at least 1 day - 25 years
Duration of glucocorticoid dosage
Duration of glucocorticoid therapy in days (measured by questionnaire; statistical evaluation on group levels; higher values are considered as being more dangerous)
Time frame: from 1 day - 25 years
Plan to share: No
Started Dec 2015 (actual). Primary completion is estimated for Jul 2029, 163 months after the start.
Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 163 months is above that.
Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2025 → Jul 2029 and completion Jul 2029 → Dec 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Po…PubMed 35159345 ↗; 4 more
Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL, Buttgereit F. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Po…PubMed 35159345 ↗; 4 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.